樂普醫療(300003.SZ)第三季度淨利潤升36.91%至4.57億元
格隆匯10月25日丨樂普醫療(300003.SZ)發佈2019年第三季度報告,實現營業收入19.59億元,同比增長20.17%;歸屬於上市公司股東的淨利潤4.57億元,同比增長36.91%;歸屬於上市公司股東的扣除非經常性損益的淨利潤4.09億元,同比增長31.98%;基本每股收益0.2582元。
前三季度,實現營業收入58.80億元,同比增長28.25%;歸屬於上市公司股東的淨利潤16.12億元,同比增長40.99%;歸屬於上市公司股東的扣除非經常性損益的淨利潤13.29億元,同比增長35.55%;基本每股收益0.9105元。經營活動產生的現金流量淨額12.81億元,同比增長35.23%。
醫療器械業務在第三季度實現較高速率增長,營業收入9.07億元,同比增長31.67%。其中原有業務繼續保持穩定較快增長,生物可吸收支架(NeoVas)自上市以來貢獻新業績增長。報告期內醫療器械業務累計實現營業收入26.53億元,同比增長27.24%,實現近年來的最快增長。
原料藥業務國內外需求旺盛,報告期內實現營業收入5.46億元,同比增長46.01%;第三季度營業收入1.41億元,同比下降6.93%,主要由於個別客户貨物延遲交付導致。
製劑業務在國家集採開始後受到一定影響,醫療機構的營銷增長有所放緩。公司硫酸氫氯吡格雷銷售數量仍有增長,但由於在醫療機構中終端銷售價格顯著降低,導致營銷收入較去年同期降低;阿託伐他汀鈣在第三季度醫療機構和OTC市場均維持較高速的增長。製劑業務第三季度營業收入8.30億元,同比增長12.56%。報告期內製劑業務累計實現營業收入24.59億元,同比增長27.25%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.